"Antibodies, Monoclonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies produced by a single clone of cells.
Descriptor ID |
D000911
|
MeSH Number(s) |
D12.776.124.486.485.114.224 D12.776.124.790.651.114.224 D12.776.377.715.548.114.224
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal".
This graph shows the total number of publications written about "Antibodies, Monoclonal" by people in this website by year, and whether "Antibodies, Monoclonal" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 18 | 19 | 37 |
1995 | 15 | 28 | 43 |
1996 | 14 | 26 | 40 |
1997 | 16 | 24 | 40 |
1998 | 12 | 24 | 36 |
1999 | 13 | 20 | 33 |
2000 | 23 | 27 | 50 |
2001 | 19 | 24 | 43 |
2002 | 27 | 32 | 59 |
2003 | 40 | 51 | 91 |
2004 | 42 | 34 | 76 |
2005 | 43 | 40 | 83 |
2006 | 63 | 30 | 93 |
2007 | 67 | 52 | 119 |
2008 | 60 | 62 | 122 |
2009 | 68 | 56 | 124 |
2010 | 84 | 57 | 141 |
2011 | 61 | 46 | 107 |
2012 | 34 | 30 | 64 |
2013 | 50 | 20 | 70 |
2014 | 37 | 35 | 72 |
2015 | 41 | 34 | 75 |
2016 | 59 | 33 | 92 |
2017 | 54 | 39 | 93 |
2018 | 59 | 18 | 77 |
2019 | 30 | 23 | 53 |
2020 | 39 | 33 | 72 |
2021 | 31 | 33 | 64 |
2022 | 10 | 52 | 62 |
2023 | 9 | 31 | 40 |
2024 | 6 | 6 | 12 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
Therapeutic administration of a cross-reactive mAb targeting the fusion glycoprotein of Nipah virus protects nonhuman primates. Sci Transl Med. 2024 Apr 03; 16(741):eadl2055.
-
Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancer. Oncotarget. 2024 Mar 19; 15:238-247.
-
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma. J Immunother Cancer. 2024 03 11; 12(3).
-
CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123. Leuk Res. 2024 04; 139:107479.
-
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nat Med. 2024 Mar; 30(3):716-729.
-
Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043. Nat Commun. 2024 Feb 01; 15(1):972.
-
Evidence to Date on the Therapeutic Potential of Zolbetuximab in Advanced Gastroesophageal Adenocarcinoma. Curr Oncol. 2024 Feb 01; 31(2):769-777.
-
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX. Blood Adv. 2024 01 23; 8(2):388-398.
-
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. Reply. N Engl J Med. 2024 Jan 18; 390(3):287-288.
-
Nectin-4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin. J Cutan Pathol. 2024 May; 51(5):360-367.